Progyny (PGNY) Competitors $22.55 -0.96 (-4.08%) As of 02:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PGNY vs. GH, OPCH, RDNT, BTSG, SHC, SGRY, CON, PRVA, WGS, and ADUSShould you be buying Progyny stock or one of its competitors? The main competitors of Progyny include Guardant Health (GH), Option Care Health (OPCH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Surgery Partners (SGRY), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), GeneDx (WGS), and Addus HomeCare (ADUS). These companies are all part of the "healthcare" industry. Progyny vs. Its Competitors Guardant Health Option Care Health RadNet BrightSpring Health Services Sotera Health Surgery Partners Concentra Group Holdings Parent Privia Health Group GeneDx Addus HomeCare Guardant Health (NASDAQ:GH) and Progyny (NASDAQ:PGNY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings. Does the media refer more to GH or PGNY? In the previous week, Guardant Health had 13 more articles in the media than Progyny. MarketBeat recorded 24 mentions for Guardant Health and 11 mentions for Progyny. Progyny's average media sentiment score of 1.40 beat Guardant Health's score of 0.79 indicating that Progyny is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Guardant Health 10 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Progyny 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, GH or PGNY? Progyny has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGuardant Health$828.85M6.21-$436.37M-$3.35-12.40Progyny$1.17B1.66$54.34M$0.5739.56 Which has more volatility & risk, GH or PGNY? Guardant Health has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Comparatively, Progyny has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Do insiders and institutionals believe in GH or PGNY? 92.6% of Guardant Health shares are owned by institutional investors. Comparatively, 94.9% of Progyny shares are owned by institutional investors. 6.1% of Guardant Health shares are owned by company insiders. Comparatively, 9.4% of Progyny shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is GH or PGNY more profitable? Progyny has a net margin of 4.33% compared to Guardant Health's net margin of -49.93%. Progyny's return on equity of 10.90% beat Guardant Health's return on equity.Company Net Margins Return on Equity Return on Assets Guardant Health-49.93% N/A -28.33% Progyny 4.33%10.90%7.20% Do analysts prefer GH or PGNY? Guardant Health presently has a consensus price target of $54.95, indicating a potential upside of 32.30%. Progyny has a consensus price target of $24.82, indicating a potential upside of 10.06%. Given Guardant Health's stronger consensus rating and higher probable upside, research analysts clearly believe Guardant Health is more favorable than Progyny.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Guardant Health 0 Sell rating(s) 0 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 3.05Progyny 0 Sell rating(s) 5 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.67 SummaryProgyny beats Guardant Health on 10 of the 16 factors compared between the two stocks. Get Progyny News Delivered to You Automatically Sign up to receive the latest news and ratings for PGNY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PGNY vs. The Competition Export to ExcelMetricProgynyMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.93B$7.09B$5.45B$9.29BDividend YieldN/A2.84%4.71%4.06%P/E Ratio39.5263.9729.4724.30Price / Sales1.6634.19418.80168.61Price / Cash68.1026.8935.8358.21Price / Book4.558.648.275.54Net Income$54.34M$239.96M$3.24B$259.03M7 Day Performance-2.42%-6.08%-3.77%-4.63%1 Month Performance2.22%-4.14%5.61%5.86%1 Year Performance-16.79%11.22%22.78%15.16% Progyny Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PGNYProgyny2.0063 of 5 stars$22.55-4.1%$24.82+10.1%-16.6%$1.93B$1.17B39.52310Positive NewsUpcoming EarningsGHGuardant Health4.7856 of 5 stars$45.64-1.8%$54.45+19.3%+16.7%$5.65B$739.02M-13.462,021News CoverageEarnings ReportAnalyst ForecastOPCHOption Care Health4.6485 of 5 stars$29.17-1.1%$35.50+21.7%-1.1%$4.78B$5.00B23.528,088News CoveragePositive NewsEarnings ReportAnalyst ForecastRDNTRadNet4.0875 of 5 stars$57.94+0.8%$69.60+20.1%-8.4%$4.35B$1.83B-134.7411,021Positive NewsBTSGBrightSpring Health Services2.7215 of 5 stars$19.71-1.2%$24.90+26.3%+66.7%$3.47B$11.27B70.3935,000News CoverageEarnings ReportGap DownSHCSotera Health2.9829 of 5 stars$11.01-0.5%$16.00+45.3%-17.2%$3.13B$1.10B137.643,000Upcoming EarningsSGRYSurgery Partners2.764 of 5 stars$22.36+0.2%$33.56+50.1%-27.7%$2.87B$3.11B-14.6115,000Positive NewsUpcoming EarningsGap UpCONConcentra Group Holdings Parent3.0194 of 5 stars$19.93+1.9%$28.50+43.0%-14.5%$2.55B$1.93B14.8711,250Positive NewsUpcoming EarningsPRVAPrivia Health Group3.802 of 5 stars$20.16+2.8%$28.38+40.8%-5.9%$2.46B$1.74B168.011,140Upcoming EarningsWGSGeneDx2.824 of 5 stars$78.35+0.6%$92.33+17.8%+211.6%$2.24B$305.45M-55.571,200Earnings ReportAnalyst ForecastInsider TradeOptions VolumeGap DownADUSAddus HomeCare4.927 of 5 stars$107.40+0.3%$142.57+32.7%-12.0%$1.98B$1.15B24.2449,703Positive NewsUpcoming Earnings Related Companies and Tools Related Companies Guardant Health Alternatives Option Care Health Alternatives RadNet Alternatives BrightSpring Health Services Alternatives Sotera Health Alternatives Surgery Partners Alternatives Concentra Group Holdings Parent Alternatives Privia Health Group Alternatives GeneDx Alternatives Addus HomeCare Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PGNY) was last updated on 8/1/2025 by MarketBeat.com Staff From Our PartnersWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!99.8% voted YES on this crypto partnership Kraken—one of the world's biggest crypto exchanges—just picked O...Crypto 101 Media | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | SponsoredWhy “The Prophet” Is Betting Big on This $10 StockAmerica's Biggest Land Grab Is Not Where You Think While the media focuses on coastal cities and farmland.....Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Progyny, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Progyny With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PGNY Stock Alerts